Cure for CLL
Derivates of para-NO-ASA for the treatment of CLL

Invention
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western countries. The disease is very heterogeneous with some patients showing extremely slow progression while others proceed rapidly into advanced disease stages and require immediate treatment. Despite considerable improvement of therapeutic strategies in the last decade, CLL remains incurable by conventional chemoimmuno-therapies. The development of new treatment options remains an important goal.

The present invention provides compounds acting as an effective and selective medicament for the treatment of neoplastic diseases or proliferative disorders, in particular compounds which induce selectively apoptosis of degenerated cells providing reduced side effects in living organisms. The compounds of the present invention are characterized by a high selectivity towards neoplastic cells. CLL cells show a higher sensitivity towards the compounds than PBMCs opening a therapeutic window. The EC\textsubscript{50} for CLL cells is in the lower micromolar range.

Furthermore, compounds have proven activity on different CLL populations. The activity against CLL cells has been shown in a xenograft model of CLL. It has been shown that compounds may be suitable for the treatment of other neoplasias.

Commercial Opportunities
On behalf of the University of Cologne, we are offering this opportunity for licensing.

Current Status
A PCT application is pending.

Relevant Publication


An invention of University of Cologne (UniKöln).

Competitive Advantages
- Compound claims towards novel derivates of para-NO-ASA
  - High selectivity
  - High activity
  - Tested on different CLL cell populations
  - Proven in a xenograft model of CLL
- Development team comprising chemists and clinicians
- Compounds may be suitable for the treatment of other neoplasias

Contact:
Ref. No.: 4045
Dr. Andreas Wagener
PROvendis GmbH
Schloßstrasse 11-15
D-45468 Muelheim an der Ruhr, Germany
Phone: +49 (0)208 94 105 38
Fax: +49 (0)208 94 105 50
Email: aw@provendis.info
Web: www.provendis.info

PROvendis GmbH is the patent licensing agency for the universities of North Rhine-Westphalia, Germany. PROvendis recommends: www.inventionstore.de - Free e-mail service to access the latest IP-protected top technologies.